Tumour Associated Antigens CA 15.3 and CA 125 in Ovarian Cancer

Lotzniker, Milvia; Pavesi, Franco; Scarabelli, M.; Vadacca, Gianfranco; Franchi, Massimo Piergiuseppe; Moratti, Remigio

doi:10.1177/172460089100600206

Cited by 7 publications

(4 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…First, we selected eight candidate biomarkers for screening high-risk ovarian cancer based on literature searches [19][20][21][22][23][24][25][26][27].…”

Section: Resultsmentioning

confidence: 99%

“…[20,21] CA15.3 CA15.3 is an aspecific tumor marker characteristic of cancer proliferation and the elevated levels of CA15.3 have been associated with ovarian malignancy, measurement of this biomarker has been proposed to be of some clinical value in combination with CA125 for diagnosis and monitoring of ovarian cancer. [22,23] ApoA2 ApoA2 is the second most abundant apolipoprotein of high-density lipoproteins, which modulate cholesterol transport and metabolism and concentrations of ApoA2 is higher in malignant compared with either borderline or benign ovarian cyst fluids.…”

Section: Ca125mentioning

confidence: 99%

See 1 more Smart Citation

Multiple biomarkers are more accurate than a combination of carbohydrate antigen 125 and human epididymis protein 4 for ovarian cancer screening

et al. 2022

View full text Add to dashboard Cite

ObjectiveThe objective of this study was to compare and evaluate the diagnostic value of serum carbohydrate antigen 125 (CA125) and/or human epididymis protein 4 (HE4) and a panel of novel multiple biomarkers in patients with ovarian tumors to identify more accurate and effective markers for screening ovarian cancer.MethodsCandidate ovarian cancer biomarkers were selected based on a literature search. Dozens of candidate biomarkers were examined using 143 serum samples from patients with ovarian cancer and 157 healthy serum samples as noncancer controls. To select the optimal marker panel for an ovarian cancer classification model, a set of biomarker panels was created with the number of possible combinations of eight biomarkers. Using the set of biomarkers as an input variable, the optimal biomarker panel was selected by examining the performance of the biomarker panel set using the Random Forest algorithm as a non-linear classification method and a 10-fold cross-validation technique.ResultsThe final selected optimal combination of five biomarkers (CA125, HE4, cancer antigen 15-3, apolipoprotein [Apo] A1, and ApoA2) exhibited a sensitivity of 93.71% and specificity of 93.63% for ovarian cancer detection during validation.ConclusionCombining multiple biomarkers is a valid strategy for ovarian cancer diagnosis and can be used as a minimally invasive screening method for early ovarian cancer. A panel of five optimal biomarkers, including CA125 and HE4, was verified in this study. These can potentially be used as clinical biomarkers for early detection of ovarian cancer.

show abstract

“…First, we selected eight candidate biomarkers for screening high-risk ovarian cancer based on literature searches [19][20][21][22][23][24][25][26][27].…”

Section: Resultsmentioning

confidence: 99%

Section: Ca125mentioning

confidence: 99%

Multiple biomarkers are more accurate than a combination of carbohydrate antigen 125 and human epididymis protein 4 for ovarian cancer screening

et al. 2022

View full text Add to dashboard Cite

show abstract

“…On the other hand, another tumor marker CA15-3, which is reported to be high in 70% of the cases with advanced ovarian carcinoma (17) , was within normal limits in all our cases with peritoneal tuberculosis contrary to the high levels of serum CA125. Because the serum CA15-3 level was not reported to be elevated in mesothelial reactions unlike the serum CA125 level (18) , the true positivity may increase when the CA15-3 level has been added to the investigation work in cases suspected with peritoneal tuberculosis.…”

Section: Discussionmentioning

confidence: 99%

Peritoneal tuberculosis simulating advanced ovarian carcinoma: is clinical impression sufficient to administer neoadjuvant chemotherapy for advanced ovarian cancer?

Gürbüz

Karateke

Kabaca

et al. 2006

Int J Gynecol Cancer

View full text Add to dashboard Cite

Peritoneal tuberculosis mimics advanced ovarian cancer because of the similarities in clinical signs and symptoms such as ascites, pelvic and abdominal pain and mass, and elevation of serum CA125 level. We have presented four cases of peritoneal tuberculosis that underwent exploratory laparotomy for suspected advanced ovarian cancer during a 3-year period. Definitive diagnosis of tuberculosis was performed at laparotomy in all the cases. The frozen-section analysis seems to be the gold standard in the differential diagnosis. In view of these data, clinical diagnosis of advanced ovarian cancer is not sufficient for administering neoadjuvant chemotherapy. Cytologic or pathologic findings must be consistent with ovarian cancer for candidates who are being considered for neoadjuvant chemotherapy.

show abstract

“…In relation to the evident correlation between MUC-1 expression and Ca 15-3, there are possible false positive results, especially in infections responsible of epithelial modifications. 13,14 …”

Section: Introductionmentioning

confidence: 99%

Role of Ca 15-3 in patients with biochemically suspected prostate cancer and multiple negative ultrasound-guided prostate biopsies

Falsaperla

Morgia

Giammusso

et al. 2003

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

Ca 15-3 is an aspecific tumor marker characteristic of cancer proliferation. Elevated serum levels seem to be closely correlated with cancer progression in non-urological tumors. This study assessed the role of Ca 15-3 as an aspecific tumor marker in patients with borderline prostate-specific antigen (PSA) biochemically suspected of prostate cancer (PCa) and with multiple negative prostate biopsies.The study is based on prospective analysis of 103 patients: (a) 33 patients (group A) presented lower urinary tract symptoms secondary to BPH with normal serum PSA values, DRE and TRUS negative for suspected PCa; (b) 31 patients (group B) with histologically diagnosed PCa; (c) 39 patients (group C) with borderline serum PSA values, DRE and TRUS normal, two ultrasound (US)-guided random prostate biopsies negative for PCa. Ca 15-3 was determined in the entire study series by the IRMA method, using as range the values proposed for the investigated non-urological tumors (38 UI/l).Ca 15-3 was within normal range in all group A patients (control), while the values were elevated in 27/31 of group B patients (PCa) and in 11/39 of group C (PCa suspected) patients. A third biopsy was performed in all 39 group C patients with borderline PSA and it was PCa-positive in 13 patients (33.3%, subgroup C3). In this series Ca 15-3 was increased in 9 of 13 patients (subgroup C3a), while the remaining four patients (subgroup C3b) presented values within the normal range. On 26 group C patients who were negative for PCa to third biopsy (subgroup C4), 24 patients had Ca 15-3 levels within normal range (subgroup C4a) with histologic findings of BPH in 23 cases and granulomatous chronic prostatitis in one case, while two patients (subgroup C4b) had elevated Ca 15-3 concentrations associated with lymphoplasmacytic chronic prostatitis.We hypothesize that Ca 15-3, as a specific tumor marker, could be an interesting and inexpensive second step diagnostic tool for PCa in patients with borderline PSA and multiple negative prostate biopsies, as it could indicate whether a repeated biopsy should be performed in a short time, having excluded other concomitant tumors. However, further prospective studies will be necessary to confirm this hypothesis.

show abstract

Tumour Associated Antigens CA 15.3 and CA 125 in Ovarian Cancer

Cited by 7 publications

References 18 publications

Multiple biomarkers are more accurate than a combination of carbohydrate antigen 125 and human epididymis protein 4 for ovarian cancer screening

Multiple biomarkers are more accurate than a combination of carbohydrate antigen 125 and human epididymis protein 4 for ovarian cancer screening

Peritoneal tuberculosis simulating advanced ovarian carcinoma: is clinical impression sufficient to administer neoadjuvant chemotherapy for advanced ovarian cancer?

Role of Ca 15-3 in patients with biochemically suspected prostate cancer and multiple negative ultrasound-guided prostate biopsies

Contact Info

Product

Resources

About